NCT03658512

Brief Summary

Diabetes mellitus is a widespread disease with increasing prevalence worldwide. Patients with diabetes can develop multiple late complications such as neuropathy, retinopathy, nephropathy and cardiovascular comorbidities. So far, there are no reliable predictive tools or markers to estimate if, when and to what extent a patient with diabetes develops late complications. For the patients quality of life and for health economic reasons an improved risk assessment would be desirable. The prospective TUEDID study will characterize diabetic patients to look out for parameters the predict progression of diabetes and its complications.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
20mo left

Started Aug 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress83%
Aug 2018Feb 2028

First Submitted

Initial submission to the registry

August 10, 2018

Completed
3 days until next milestone

Study Start

First participant enrolled

August 13, 2018

Completed
23 days until next milestone

First Posted

Study publicly available on registry

September 5, 2018

Completed
9.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2028

Last Updated

August 29, 2022

Status Verified

August 1, 2022

Enrollment Period

9.5 years

First QC Date

August 10, 2018

Last Update Submit

August 24, 2022

Conditions

Diabetes Mellitus

Outcome Measures

Primary Outcomes (2)

  • Glycemic control (blood glucose)

    Assessed as fasting blood glucose and HbA1C

    At enrolment

  • Glycemic control (HbA1C)

    Assessed as fasting HbA1C

    At enrolment

Other Outcomes (28)

  • Liver function

    At enrolment

  • Renal function

    At enrolment

  • Glomerular filtration rate (GFR)

    At enrolment

  • +25 more other outcomes

Study Arms (1)

TUEDID cohort

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

People with or without diabetes who are treated at the University Hospital Tübingen

You may qualify if:

  • \>18 years

You may not qualify if:

  • no written informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Tuebingen, Internal medicine IV

Tübingen, 72074, Germany

RECRUITING

MeSH Terms

Conditions

Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Central Study Contacts

Andreas Fritsche, MD

CONTACT

+49 7071 29 80687andreas.fritsche@med.uni-tuebingen.de

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 10, 2018

First Posted

September 5, 2018

Study Start

August 13, 2018

Primary Completion (Estimated)

February 1, 2028

Study Completion (Estimated)

February 1, 2028

Last Updated

August 29, 2022

Record last verified: 2022-08

Data Sharing

IPD Sharing
Will not share

Locations

DE(1)